Literature DB >> 25169560

Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.

Theodoros Kelesidis1, Judith S Currier2.   

Abstract

The pathogenesis of atherosclerosis in human immunodeficiency virus (HIV)-infected individuals is incompletely understood and appears to be multifactorial. Proatherogenic changes in blood and tissue lipids are associated with an increased risk of cardiovascular disease among HIV-infected subjects, and these changes may be both quantitative (dyslipidemia) and qualitative. In view of the pivotal role of dyslipidemia in the process of atherosclerosis, the increased incidence of dyslipidemia in HIV-infected individuals, and the emerging role of lipid abnormalities in systemic pathophysiologic processes such as immune activation, we review the contributions of dyslipidemia to cardiovascular risk in HIV infection.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiretroviral therapy; Cardiovascular risk; Dyslipidemia; Human immunodeficiency virus

Mesh：

Year:  2014        PMID： 25169560      PMCID： PMC5054418          DOI： 10.1016/j.ecl.2014.06.003

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.748


  97 in total

Review 1.  Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - a review of the experimental evidence.

Authors:  Harry Björkbacka; Gunilla Nordin Fredrikson; Jan Nilsson
Journal:  Atherosclerosis       Date:  2012-11-06       Impact factor: 5.162

2.  Hypertriglyceridemia in the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; D P Kotler; R Hamadeh; A Tierney; J Wang; R N Pierson
Journal:  Am J Med       Date:  1989-01       Impact factor: 4.965

Review 3.  Metabolic disease in HIV infection.

Authors:  Jordan E Lake; Judith S Currier
Journal:  Lancet Infect Dis       Date:  2013-11       Impact factor: 25.071

4.  Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.

Authors:  Judith A Aberg; Pablo Tebas; Edgar Turner Overton; Samir K Gupta; Paul E Sax; Alan Landay; Ron Falcon; Robert Ryan; Guy De La Rosa
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-02       Impact factor: 2.205

Review 5.  HIV and coronary heart disease: time for a better understanding.

Authors:  Franck Boccara; Sylvie Lang; Catherine Meuleman; Stephane Ederhy; Murielle Mary-Krause; Dominique Costagliola; Jacqueline Capeau; Ariel Cohen
Journal:  J Am Coll Cardiol       Date:  2013-02-05       Impact factor: 24.094

6.  Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.

Authors:  Daria Gotti; Bruno Mario Cesana; Laura Albini; Alessandra Calabresi; Ilaria Izzo; Emanuele Focà; Davide Motta; Rita Bellagamba; Rita Fezza; Pasquale Narciso; Laura Sighinolfi; Paolo Maggi; Nigritella Brianese; Eugenia Quiros-Roldan; Giovanni Guaraldi; Carol Torti
Journal:  HIV Clin Trials       Date:  2012 Sep-Oct

7.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

8.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

9.  Relationship between microbial translocation and endothelial function in HIV infected patients.

Authors:  Emily Blodget; Changyu Shen; Grace Aldrovandi; Adrienne Rollie; Samir K Gupta; James H Stein; Michael P Dubé
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

10.  Human immunodeficiency virus impairs reverse cholesterol transport from macrophages.

Authors:  Zahedi Mujawar; Honor Rose; Matthew P Morrow; Tatiana Pushkarsky; Larisa Dubrovsky; Nigora Mukhamedova; Ying Fu; Anthony Dart; Jan M Orenstein; Yuri V Bobryshev; Michael Bukrinsky; Dmitri Sviridov
Journal:  PLoS Biol       Date:  2006-10       Impact factor: 8.029
View more
  16 in total

Review 1.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

2.  HIV Drug Therapy in the Americas 16-18 April 2015, Mexico City, Mexico.

Authors: 
Journal:  J Int AIDS Soc       Date:  2015-04-16       Impact factor: 5.396

3.  Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.

Authors:  L T Vernon; Plp Jayashantha; M M Chidzonga; M C Komesu; R G Nair; N W Johnson
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

4.  Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children.

Authors:  Kunjal Patel; Jane Lindsey; Konstantia Angelidou; Grace Aldrovandi; Paul Palumbo
Journal:  AIDS       Date:  2018-10-23       Impact factor: 4.177

5.  Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals.

Authors:  Theodoros Kelesidis; Michael N Oda; Mark S Borja; Yumin Yee; Kit F Ng; Diana Huynh; David Elashoff; Judith S Currier
Journal:  J Acquir Immune Defic Syndr       Date:  2017-07-01       Impact factor: 3.771

6.  Dysfunctional high-density lipoprotein from HIV+ individuals promotes monocyte-derived foam cell formation in vitro.

Authors:  Thomas A Angelovich; Anna C Hearps; Michael N Oda; Mark S Borja; Diana Huynh; Stefanie Homann; Anthony Jaworowski; Theodoros Kelesidis
Journal:  AIDS       Date:  2017-11-13       Impact factor: 4.632

7.  Acute aflatoxin B1 - Induced hepatotoxicity alters gene expression and disrupts lipid and lipoprotein metabolism in rats.

Authors:  Oluwakemi Anuoluwapo Rotimi; Solomon Oladapo Rotimi; Chibueze Uchechukwu Duru; Ogheneworo Joel Ebebeinwe; Anthonia Obhio Abiodun; Boluwaji Oluwamayowa Oyeniyi; Francis Adedayo Faduyile
Journal:  Toxicol Rep       Date:  2017-07-24

8.  Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.

Authors:  Jason V Baker; Shweta Sharma; Amit C Achhra; Jose Ignacio Bernardino; Johannes R Bogner; Daniel Duprez; Sean Emery; Brian Gazzard; Jonathan Gordin; Greg Grandits; Andrew N Phillips; Siegfried Schwarze; Elsayed Z Soliman; Stephen A Spector; Giuseppe Tambussi; Jens Lundgren
Journal:  J Am Heart Assoc       Date:  2017-05-22       Impact factor: 5.501

9.  Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.

Authors:  Theodoros Kelesidis; Thuy Tien T Tran; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Otto O Yang; Grace A McComsey; James H Stein; Judith S Currier
Journal:  Antivir Ther       Date:  2016-09-23       Impact factor: 1.679

Review 10.  Multiple Infectious Agents and the Origins of Atherosclerotic Coronary Artery Disease.

Authors:  James S Lawson
Journal:  Front Cardiovasc Med       Date:  2016-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.